Analysis of messy longitudinal data from a randomized clinical trial

W Qian (Corresponding Author), M K B Parmar, R J Sambrook, P M Fayers, D J Girling, R.J. Stephens

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The randomized clinical trial, LU19, conducted by the Medical Research Council Lung Cancer Working Party, was designed to compare ACE (doxorubicin, cyclophosphamide and etoposide) chemotherapy plus G-CSF (granulocyte colony-stimulating factor) at 2-week intervals versus ACE chemotherapy alone at standard 3-week intervals in patients with small-cell lung cancer. This trial investigated whether more intensive administration of ACE would improve overall survival and affect the quality of life of patients. The report on overall survival and other outcome measures will be published in the Journal of Clinical Oncology. In this paper we focus on methods of analysing aspects of data reflecting quality of life. Twelve symptoms of lung cancer and its treatment - cough, haemoptysis, pain, nausea, vomiting, hoarse voice, sore mouth, rash, lethargy, lack of appetite, alopecia, and dysphagia - were scheduled to be assessed on seven occasions for the ACE arm and on eight occasions for the ACE+G-CSF arm by clinicians during the first 18 weeks of the treatment period. However, in practice the number of assessment forms completed per patient ranged from 1 to 9, and assessment time-points were very different from those planned. These 'messy' longitudinal data are explored by both a summary measure approach, in which experience of a symptom is summarized by a single value, and an extensive model-based statistical approach, which explicitly takes into account correlation within repeated measures. These analyses provide a clear picture of symptom comparisons between the two treatments. The application of various methods offers not only an approach to assessing the robustness of the results but also a basis for investigating reasons for inconsistency of results across methods. We conclude that except lethargy, which is worse in the ACE+G-CSF arm, all symptoms are similar across the two arms during the treatment period.
Original languageEnglish
Pages (from-to)2657-2674
Number of pages13
JournalStatistics in Medicine
Volume19
Issue number19
Early online date7 Sep 2000
DOIs
Publication statusPublished - 15 Oct 2000

Fingerprint

Randomized Clinical Trial
Longitudinal Data
Arm
Granulocyte Colony-Stimulating Factor
Randomized Controlled Trials
Lethargy
Quality of Life
Lung Cancer
Chemotherapy
Lung Neoplasms
Small Cell Lung Cancer
Nausea
Vomiting
Drug Therapy
Oncology
Interval
Repeated Measures
Survival
Medical Oncology
Hemoptysis

Keywords

  • Amsacrine
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Small Cell
  • Cytarabine
  • Data Interpretation, Statistical
  • Etoposide
  • Granulocyte Colony-Stimulating Factor
  • Humans
  • Lung Neoplasms
  • Models, Statistical
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Time Factors

Cite this

Analysis of messy longitudinal data from a randomized clinical trial. / Qian, W (Corresponding Author); Parmar, M K B; Sambrook, R J; Fayers, P M; Girling, D J; Stephens, R.J.

In: Statistics in Medicine, Vol. 19, No. 19, 15.10.2000, p. 2657-2674.

Research output: Contribution to journalArticle

Qian, W ; Parmar, M K B ; Sambrook, R J ; Fayers, P M ; Girling, D J ; Stephens, R.J. / Analysis of messy longitudinal data from a randomized clinical trial. In: Statistics in Medicine. 2000 ; Vol. 19, No. 19. pp. 2657-2674.
@article{f2f964e2a2924097b7c024910a8e8605,
title = "Analysis of messy longitudinal data from a randomized clinical trial",
abstract = "The randomized clinical trial, LU19, conducted by the Medical Research Council Lung Cancer Working Party, was designed to compare ACE (doxorubicin, cyclophosphamide and etoposide) chemotherapy plus G-CSF (granulocyte colony-stimulating factor) at 2-week intervals versus ACE chemotherapy alone at standard 3-week intervals in patients with small-cell lung cancer. This trial investigated whether more intensive administration of ACE would improve overall survival and affect the quality of life of patients. The report on overall survival and other outcome measures will be published in the Journal of Clinical Oncology. In this paper we focus on methods of analysing aspects of data reflecting quality of life. Twelve symptoms of lung cancer and its treatment - cough, haemoptysis, pain, nausea, vomiting, hoarse voice, sore mouth, rash, lethargy, lack of appetite, alopecia, and dysphagia - were scheduled to be assessed on seven occasions for the ACE arm and on eight occasions for the ACE+G-CSF arm by clinicians during the first 18 weeks of the treatment period. However, in practice the number of assessment forms completed per patient ranged from 1 to 9, and assessment time-points were very different from those planned. These 'messy' longitudinal data are explored by both a summary measure approach, in which experience of a symptom is summarized by a single value, and an extensive model-based statistical approach, which explicitly takes into account correlation within repeated measures. These analyses provide a clear picture of symptom comparisons between the two treatments. The application of various methods offers not only an approach to assessing the robustness of the results but also a basis for investigating reasons for inconsistency of results across methods. We conclude that except lethargy, which is worse in the ACE+G-CSF arm, all symptoms are similar across the two arms during the treatment period.",
keywords = "Amsacrine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Small Cell, Cytarabine, Data Interpretation, Statistical, Etoposide, Granulocyte Colony-Stimulating Factor, Humans, Lung Neoplasms, Models, Statistical, Quality of Life, Randomized Controlled Trials as Topic, Time Factors",
author = "W Qian and Parmar, {M K B} and Sambrook, {R J} and Fayers, {P M} and Girling, {D J} and R.J. Stephens",
year = "2000",
month = "10",
day = "15",
doi = "10.1002/1097-0258(20001015)19:19<2657::AID-SIM557>3.0.CO;2-3",
language = "English",
volume = "19",
pages = "2657--2674",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "19",

}

TY - JOUR

T1 - Analysis of messy longitudinal data from a randomized clinical trial

AU - Qian, W

AU - Parmar, M K B

AU - Sambrook, R J

AU - Fayers, P M

AU - Girling, D J

AU - Stephens, R.J.

PY - 2000/10/15

Y1 - 2000/10/15

N2 - The randomized clinical trial, LU19, conducted by the Medical Research Council Lung Cancer Working Party, was designed to compare ACE (doxorubicin, cyclophosphamide and etoposide) chemotherapy plus G-CSF (granulocyte colony-stimulating factor) at 2-week intervals versus ACE chemotherapy alone at standard 3-week intervals in patients with small-cell lung cancer. This trial investigated whether more intensive administration of ACE would improve overall survival and affect the quality of life of patients. The report on overall survival and other outcome measures will be published in the Journal of Clinical Oncology. In this paper we focus on methods of analysing aspects of data reflecting quality of life. Twelve symptoms of lung cancer and its treatment - cough, haemoptysis, pain, nausea, vomiting, hoarse voice, sore mouth, rash, lethargy, lack of appetite, alopecia, and dysphagia - were scheduled to be assessed on seven occasions for the ACE arm and on eight occasions for the ACE+G-CSF arm by clinicians during the first 18 weeks of the treatment period. However, in practice the number of assessment forms completed per patient ranged from 1 to 9, and assessment time-points were very different from those planned. These 'messy' longitudinal data are explored by both a summary measure approach, in which experience of a symptom is summarized by a single value, and an extensive model-based statistical approach, which explicitly takes into account correlation within repeated measures. These analyses provide a clear picture of symptom comparisons between the two treatments. The application of various methods offers not only an approach to assessing the robustness of the results but also a basis for investigating reasons for inconsistency of results across methods. We conclude that except lethargy, which is worse in the ACE+G-CSF arm, all symptoms are similar across the two arms during the treatment period.

AB - The randomized clinical trial, LU19, conducted by the Medical Research Council Lung Cancer Working Party, was designed to compare ACE (doxorubicin, cyclophosphamide and etoposide) chemotherapy plus G-CSF (granulocyte colony-stimulating factor) at 2-week intervals versus ACE chemotherapy alone at standard 3-week intervals in patients with small-cell lung cancer. This trial investigated whether more intensive administration of ACE would improve overall survival and affect the quality of life of patients. The report on overall survival and other outcome measures will be published in the Journal of Clinical Oncology. In this paper we focus on methods of analysing aspects of data reflecting quality of life. Twelve symptoms of lung cancer and its treatment - cough, haemoptysis, pain, nausea, vomiting, hoarse voice, sore mouth, rash, lethargy, lack of appetite, alopecia, and dysphagia - were scheduled to be assessed on seven occasions for the ACE arm and on eight occasions for the ACE+G-CSF arm by clinicians during the first 18 weeks of the treatment period. However, in practice the number of assessment forms completed per patient ranged from 1 to 9, and assessment time-points were very different from those planned. These 'messy' longitudinal data are explored by both a summary measure approach, in which experience of a symptom is summarized by a single value, and an extensive model-based statistical approach, which explicitly takes into account correlation within repeated measures. These analyses provide a clear picture of symptom comparisons between the two treatments. The application of various methods offers not only an approach to assessing the robustness of the results but also a basis for investigating reasons for inconsistency of results across methods. We conclude that except lethargy, which is worse in the ACE+G-CSF arm, all symptoms are similar across the two arms during the treatment period.

KW - Amsacrine

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Small Cell

KW - Cytarabine

KW - Data Interpretation, Statistical

KW - Etoposide

KW - Granulocyte Colony-Stimulating Factor

KW - Humans

KW - Lung Neoplasms

KW - Models, Statistical

KW - Quality of Life

KW - Randomized Controlled Trials as Topic

KW - Time Factors

U2 - 10.1002/1097-0258(20001015)19:19<2657::AID-SIM557>3.0.CO;2-3

DO - 10.1002/1097-0258(20001015)19:19<2657::AID-SIM557>3.0.CO;2-3

M3 - Article

C2 - 10986540

VL - 19

SP - 2657

EP - 2674

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 19

ER -